The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995–2005

Malaria Journal

Table 1 Characteristics of drug trials where genotyping was performed (n = 91)

Characteristic	N (%)
Source of sample
filter paper	70 (77%)
whole blood/RBC pellet *	12 (13%)
not reported	9 (10%)
Method of DNA extraction
Chelex	38 (42%)
phenol/chloroform	17 (19%)
commercial kit	11 (12%)
methanol	1 (1%)
not reported	24 (26%)
Markers used
msp1 alone	2 (2%)
msp2 alone	20 (22%)
msp1 and msp2	19 (21%)
msp1, msp2 and glurp	46 (51%)
msp1, msp2 and others ^†	2 (2%)
not reported	2 (2%)
Interpretation of mixed results ^‡
always a recrudescence	56 (62%)
always a new infection	17 (19%)
> half of RP alleles match baseline ^§	5 (5%)
not reported	13 (14%)

* One study used either filter paper or whole blood.
^† One study used msp1, msp2 and csp. Another used msp1, msp2, glurp, trap, and pf60.1.
^‡ A mixed result is defined here as a recurrent parasitaemia sample which shows both alleles that were present in the baseline sample as well as new alleles not seen at baseline.
^§ RP = Recurrent parasitaemia sample. Four of five studies used msp2 alone and defined recrudescence as > half of RP alleles matching alleles found in the baseline sample. One study used msp1, msp2 and glurp and required a majority of RP alleles match baseline for every locus tested.

ISSN: 1475-2875